Tadashi Maeda

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Clinical differentiation of infectious mononucleosis that is caused by Epstein-Barr virus or cytomegalovirus: A single-center case-control study in Japan

Takamasa Ishii, Yosuke Sasaki, Tadashi Maeda et al. · Journal of Infection and Chemotherapy · 2019 · 79 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +11

Role of infected grandmothers in transmission of <i><scp>H</scp>elicobacter pylori</i> to children in a <scp>J</scp>apanese rural town

Yoshihisa Urita, Toshiyasu Watanabe, Naoyuki Kawagoe et al. · Journal of Paediatrics and Child Health · 2013 · 77 citations

Life Sciences, Infectious Diseases, Microbiology +9

Effect of nebulized furosemide in terminally ill cancer patients with dyspnea

Hiroyuki Kohara, Hiroshi Ueoka, Keisuke Aoe et al. · Journal of Pain and Symptom Management · 2003 · 77 citations · Full text

Medicine, Oncology, Pharmacology +12